Fudan Zhangjiang (01349) saw its shares decline by more than 4%. As of the time of writing, the stock was down 4.15%, trading at HK$3, with a turnover of HK$7.522 million. The movement follows the company's release of its 2025 performance report on February 27. The report indicated an operating revenue of approximately RMB 686 million, a decrease of 3.33% year-on-year. The company recorded a net loss attributable to shareholders of about RMB 157 million, shifting from a profit to a loss compared to the previous year. During the reporting period, the group's production and operations remained normal, with no changes to the main types of drugs marketed and sold. However, as Doxorubicin Hydrochloride Liposome Injection was included in the national centralized procurement catalog, the company's product Libao® was not selected. In accordance with the relevant procurement rules and changes in the competitive market landscape, the company adjusted the sales strategy for Libao® during the period. This included, but was not limited to, a gradual reduction of its market retail price starting from May 1, 2025, leading to a corresponding decrease in its profit margin.